Literature DB >> 32236871

Complications of Phosphate and Vitamin D Treatment in X-Linked Hypophosphataemia.

Pedro Arango Sancho1.   

Abstract

Conventional treatment of X-linked hypophosphataemia (XLH) consists in the oral administration of phosphate plus calcitriol supplements. Although this therapy has reduced bone deformities and even achieved adequate patient growth, overtreatment or low adherence could lead to subsequent consequences that may compromise the efficacy of the therapy. Some of the complications associated with phosphate and vitamin D treatment are abdominal discomfort, diarrhoea, hypokalaemia, hyperparathyroidism, hypercalcaemia or hypercalciuria, nephrocalcinosis or nephrolithiasis, and ectopic calcifications. Therefore, constant multidisciplinary monitoring of patients with XLH is necessary to prevent the manifestation of these complications and to deal with them as soon as they appear. The main objective of this article is to review the main complications arising from conventional treatment of XLH and how to deal with them.

Entities:  

Keywords:  FGF23; Growth hormone; Hypercalcaemia; Hyperparathyroidism; Nephrocalcinosis

Mesh:

Substances:

Year:  2020        PMID: 32236871     DOI: 10.1007/s12325-019-01170-7

Source DB:  PubMed          Journal:  Adv Ther        ISSN: 0741-238X            Impact factor:   3.845


  5 in total

Review 1.  Disorders of phosphate homeostasis in children, part 2: hypophosphatemic and hyperphosphatemic disorders.

Authors:  Richard M Shore
Journal:  Pediatr Radiol       Date:  2022-05-10

2.  X-linked Hypophosphatemic Rickets: Awareness, Knowledge, and Practice of Pediatric Endocrinologists in Arab Countries.

Authors:  Asma Deeb; Fahad Al Juraibah; Muhammad Al Dubayee; Abdelhadi Habeb
Journal:  J Pediatr Genet       Date:  2020-12-15

3.  Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.

Authors:  Fahad Al Juraibah; Elham Al Amiri; Mohammed Al Dubayee; Jamal Al Jubeh; Hessa Al Kandari; Afaf Al Sagheir; Adnan Al Shaikh; Salem A Beshyah; Asma Deeb; Abdelhadi Habeb; Manal Mustafa; Hanaa Zidan; M Zulf Mughal
Journal:  Arch Osteoporos       Date:  2021-03-04       Impact factor: 2.617

4.  Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial.

Authors:  Noriyuki Namba; Takuo Kubota; Koji Muroya; Hiroyuki Tanaka; Masanori Kanematsu; Masahiro Kojima; Shunichiro Orihara; Hironori Kanda; Yoshiki Seino; Keiichi Ozono
Journal:  J Endocr Soc       Date:  2022-02-11

Review 5.  Cellular and Molecular Alterations Underlying Abnormal Bone Growth in X-Linked Hypophosphatemia.

Authors:  Rocío Fuente; María García-Bengoa; Ángela Fernández-Iglesias; Helena Gil-Peña; Fernando Santos; José Manuel López
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.